Bausch + Lomb begins distribution of Vyzulta
Vyzulta, indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, is now being distributed by Bausch + Lomb to U.S. wholesale pharmaceutical distributors.
Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) is the first prostaglandin analogue with one of its metabolites being nitric oxide, according to a press release from Valeant Pharmaceuticals.
The drug will be available to patients in the next several days.
“We’re excited that Vyzulta is now available as a treatment option for people suffering from glaucoma,” Joseph C. Papa, chairman and CEO of Valeant, said in the release. “We remain committed to developing new innovative eye health medicines that can help address current and emerging unmet medical needs, particularly as the global population continues to advance in age.”